Marcus Goncalves, M.D., PH.D
NPI: 1992071518
Total Payments
$81,605
2024 Payments
$13,119
Companies
5
Transactions
31
Medicare Patients
170
Medicare Billing
$25,646
Payment Breakdown by Category
Consulting$35,042 (42.9%)
Research$29,928 (36.7%)
Other$14,985 (18.4%)
Travel$1,108 (1.4%)
Food & Beverage$541.65 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $35,042 | 10 | 42.9% |
| Unspecified | $29,928 | 8 | 36.7% |
| Honoraria | $14,985 | 3 | 18.4% |
| Travel and Lodging | $1,108 | 4 | 1.4% |
| Food and Beverage | $541.65 | 6 | 0.7% |
Payments by Type
General
$51,676
23 transactions
Research
$29,928
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40,477 | 17 | $0 (2024) |
| PFIZER INC. | $27,727 | 8 | $0 (2023) |
| Genentech, Inc. | $10,640 | 1 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $2,573 | 3 | $0 (2017) |
| Novo Nordisk Inc | $187.21 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,119 | 3 | Genentech, Inc. ($10,640) |
| 2023 | $18,205 | 4 | PFIZER INC. ($11,655) |
| 2022 | $21,212 | 8 | PFIZER INC. ($13,505) |
| 2021 | $7,056 | 3 | Novartis Pharmaceuticals Corporation ($5,576) |
| 2020 | $15,993 | 3 | Novartis Pharmaceuticals Corporation ($15,975) |
| 2019 | $3,248 | 5 | Novartis Pharmaceuticals Corporation ($2,260) |
| 2018 | $81.25 | 1 | PFIZER INC. ($81.25) |
| 2017 | $2,691 | 4 | Bayer HealthCare Pharmaceuticals Inc. ($2,573) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/02/2024 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $2,409.44 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 06/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $69.29 | General |
| 04/29/2024 | Genentech, Inc. | Perjeta (Biological) | Consulting Fee | Cash or cash equivalent | $10,640.00 | General |
| Category: BioOncology | ||||||
| 09/09/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $396.11 | Research |
| Study: BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC • Category: Oncology | ||||||
| 06/09/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $9,620.00 | General |
| 04/26/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,035.00 | General |
| 01/31/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $6,153.93 | Research |
| Study: Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat • Category: Oncology | ||||||
| 11/21/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $443.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 08/08/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $343.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $176.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 06/10/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.75 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2022 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $10,915.00 | General |
| 04/14/2022 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $2,590.00 | General |
| 03/30/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $3,344.25 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $1,480.00 | General |
| 04/28/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.50 | General |
| Category: ONCOLOGY | ||||||
| 02/18/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $4,375.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PIQRAY RESEARCH • Category: ONCOLOGY | ||||||
| 12/24/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $13,125.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 03/02/2020 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $18.29 | General |
| 01/09/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $2,850.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Consulting Fee | Cash or cash equivalent | $2,058.00 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Food and Beverage | In-kind items and services | $109.40 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Travel and Lodging | Cash or cash equivalent | $58.06 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Travel and Lodging | In-kind items and services | $35.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $15,975 | 2 |
| Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat | Novartis Pharmaceuticals Corporation | $6,154 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $4,375 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $2,409 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $619.00 | 2 |
| BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC | Novartis Pharmaceuticals Corporation | $396.11 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 33 | 44 | $18,700 | $4,645 |
| 2022 | 1 | 31 | 54 | $20,655 | $5,818 |
| 2021 | 3 | 60 | 73 | $29,205 | $9,789 |
| 2020 | 3 | 46 | 60 | $21,930 | $5,394 |
Total Patients
170
Total Services
231
Medicare Billing
$25,646
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 44 | $18,700 | $4,645 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 54 | $20,655 | $5,818 | 28.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 44 | $14,960 | $5,043 | 33.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 14 | $6,370 | $2,412 | 37.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $7,875 | $2,333 | 29.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 31 | $10,540 | $2,301 | 21.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $8,400 | $2,181 | 26.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 13 | $2,990 | $912.73 | 30.5% |
About Marcus Goncalves, M.D., PH.D
Marcus Goncalves, M.D., PH.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2012. The National Provider Identifier (NPI) number assigned to this provider is 1992071518.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Marcus Goncalves, M.D., PH.D has received a total of $81,605 in payments from pharmaceutical and medical device companies, with $13,119 received in 2024. These payments were reported across 31 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($35,042).
As a Medicare-enrolled provider, Goncalves has provided services to 170 Medicare beneficiaries, totaling 231 services with total Medicare billing of $25,646. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Diabetes & Metabolism
- Location New York, NY
- Active Since 03/28/2012
- Last Updated 09/28/2018
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1992071518
Products in Payments
- PIQRAY (Drug) $38,217
- Perjeta (Biological) $10,640
- Non-Covered $2,573
- BYL719 (Drug) $2,260
- Saxenda (Drug) $117.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in New York
Dr. Saakshi Khattri, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1.7M
Student in an Organized Health Care Education/Training Program $1.7M
Cheguevara Afaneh, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $1.5M
Student in an Organized Health Care Education/Training Program $1.5M
John Allan, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $550,557
Student in an Organized Health Care Education/Training Program $550,557
Jose Scher, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $496,980
Student in an Organized Health Care Education/Training Program $496,980
Dr. Anthony Rossi, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $442,377
Student in an Organized Health Care Education/Training Program $442,377
Anuradha Lala-Trindade
Student in an Organized Health Care Education/Training Program — Payments: $284,341
Student in an Organized Health Care Education/Training Program $284,341